Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101
Hiroshi Fukushima, Soichiro Yoshida, Shugo Yajima, Wei Chen, Hiroyuki Sato, Akihiro Hirakawa, Motohiro Fujiwara, Yuki Arita, Yosuke Yasuda, Hajime Tanaka, Hitoshi Masuda, Yasuhisa FujiiPURPOSE
JAVELIN Renal 101 revealed that avelumab plus axitinib improved progression-free survival (PFS) compared with sunitinib in advanced renal cell carcinoma. However, Japanese subgroup estimates were imprecise. In this study, we evaluated how Bayesian borrowing assumptions translate into posterior probabilities for this subgroup.
PATIENTS AND METHODS
Using published summary data from JAVELIN Renal 101, we modeled PFS on the log hazard-ratio scale with a normal-normal framework, comparing a weakly informative neutral prior with informative borrowing priors centered on the global final estimate (with sensitivity to the third interim estimate). Outputs were posterior HRs, 95% credible intervals (CrIs),
RESULTS
Under the neutral prior, evidence for PFS benefit in the Japanese subgroup was moderate (
CONCLUSION
A paired Bayesian strategy, graded priors for efficacy and no-borrowing priors for safety, produced transparent posterior probability summaries for the Japanese subgroup. This framework illustrates how borrowing can narrow uncertainty when exchangeability is plausible, while clarifying toxicity domains that may warrant closer monitoring, using published trial data.